Immunogenicity and efficacy of two types of West Nile virus-like particles different in size and maturation as a second-generation vaccine candidate

Vaccine

Volumn 28, Issue 40, 2010, Pages 6588-6596

  Ohtaki, Naohiro ^a   Takahashi, Hidehiro ^a   Kaneko, Keiko ^a   Gomi, Yasuyuki ^b   Ishikawa, Toyokazu ^b   Higashi, Yasushi ^b   Kurata, Takeshi ^a   Sata, Tetsutaro ^a   Kojima, Asato ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b Osaka University   (Japan)

Author keywords

Particle size; Virus like particle; West Nile vaccine

Indexed keywords

IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; NEUTRALIZING ANTIBODY; PROTEIN E6; PROTEIN PRM; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN; VIRUS LIKE PARTICLE ANTIGEN; VIRUS PROTEIN; WEST NILE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELL CLONE; CHO CELL; CONTROLLED STUDY; CROSS REACTION; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FLAVIVIRUS INFECTION; GENE EXPRESSION; IMMUNIZATION; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; LOW DRUG DOSE; MATURATION; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTECTION; SEDIMENTATION; SUCROSE DENSITY GRADIENT CENTRIFUGATION; VERO CELL; VIRION; VIRUS ENVELOPE; VIRUS GENE; VIRUS LIKE AGENT; VIRUS PARTICLE; WEST NILE FLAVIVIRUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CENTRIFUGATION, DENSITY GRADIENT; CHO CELLS; CRICETINAE; CRICETULUS; IMMUNOGLOBULIN G; MICE; MICE, INBRED C3H; PARTICLE SIZE; VACCINES, VIRUS-LIKE PARTICLE; VIRAL ENVELOPE PROTEINS; VIRAL MATRIX PROTEINS; WEST NILE FEVER; WEST NILE VIRUS; WEST NILE VIRUS VACCINES;

EID: 77956396746     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.07.055     Document Type: Article

References (42)

1. Dauphin G., Zientara S. West Nile virus: recent trends in diagnosis and vaccine development. Vaccine 2007, 25(July (30)):5563-5576.
2. Iwamoto M., Jernigan D.B., Guasch A., Trepka M.J., Blackmore C.G., Hellinger W.C., et al. Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med 2003, 348(May (22)):2196-2203.
3. Pealer L.N., Marfin A.A., Petersen L.R., Lanciotti R.S., Page P.L., Stramer S.L., et al. Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med 2003, 349(September (13)):1236-1245.
4. Kuhn R.J., Zhang W., Rossmann M.G., Pletnev S.V., Corver J., Lenches E., et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 2002, 108(March (5)):717-725.
5. Mukhopadhyay S., Kim B.S., Chipman P.R., Rossmann M.G., Kuhn R.J. Structure of West Nile virus. Science 2003, 302(October (5643)):248.
6. Lorenz I.C., Allison S.L., Heinz F.X., Helenius A. Folding and dimerization of tick-borne encephalitis virus envelope proteins prM and E in the endoplasmic reticulum. J Virol 2002, 76(June (11)):5480-5491.
7. Li L., Lok S.M., Yu I.M., Zhang Y., Kuhn R.J., Chen J., et al. The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science 2008, 319(March (5871)):1830-1834.
8. Zhang Y., Kaufmann B., Chipman P.R., Kuhn R.J., Rossmann M.G. Structure of immature West Nile virus. J Virol 2007, 81(June (11)):6141-6145.
9. Hanna S.L., Pierson T.C., Sanchez M.D., Ahmed A.A., Murtadha M.M., Doms R.W. N-linked glycosylation of west nile virus envelope proteins influences particle assembly and infectivity. J Virol 2005, 79(November (21)):13262-13274.
10. Konishi E., Pincus S., Paoletti E., Shope R.E., Burrage T., Mason P.W. Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection. Virology 1992, 188(June (2)):714-720.
11. Mutoh E., Ishikawa T., Takamizawa A., Kurata T., Sata T., Kojima A. Japanese encephalitis subunit vaccine composed of virus-like envelope antigen particles purified from serum-free medium of a high-producer J12#26 cell clone. Vaccine 2004, 22(June (20)):2599-2608.
12. Schalich J., Allison S.L., Stiasny K., Mandl C.W., Kunz C., Heinz F.X. Recombinant subviral particles from tick-borne encephalitis virus are fusogenic and provide a model system for studying flavivirus envelope glycoprotein functions. J Virol 1996, 70(July (7)):4549-4557.
13. Takahashi H., Ohtaki N., Maeda-Sato M., Tanaka M., Tanaka K., Sawa H., et al. Effects of the number of amino acid residues in the signal segment upstream or downstream of the NS2B-3 cleavage site on production and secretion of prM/M-E virus-like particles of West Nile virus. Microbes Infect 2009, 11(November (13)):1019-1028.
14. Ferlenghi I., Clarke M., Ruttan T., Allison S.L., Schalich J., Heinz F.X., et al. Molecular organization of a recombinant subviral particle from tick-borne encephalitis virus. Mol Cell 2001, 7(March (3)):593-602.
15. Mason P.W., Pincus S., Fournier M.J., Mason T.L., Shope R.E., Paoletti E. Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection. Virology 1991, 180(January (1)):294-305.
16. Chiba N., Osada M., Komoro K., Mizutani T., Kariwa H., Takashima I. Protection against tick-borne encephalitis virus isolated in Japan by active and passive immunization. Vaccine 1999, 17(March (11-12)):1532-1539.
17. Diamond M.S., Shrestha B., Marri A., Mahan D., Engle M. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J Virol 2003, 77(February (4)):2578-2586.
18. Engle M.J., Diamond M.S. Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice. J Virol 2003, 77(December (24)):12941-12949.
19. Oya A. Japanese encephalitis vaccine. Acta Paediatr Jpn 1988, 30(April (2)):175-184.
20. Widman D.G., Ishikawa T., Fayzulin R., Bourne N., Mason P.W. Construction and characterization of a second-generation pseudoinfectious West Nile virus vaccine propagated using a new cultivation system. Vaccine 2008, 26(May (22)):2762-2771.
21. Yu L., Robert Putnak J., Pletnev A.G., Markoff L. Attenuated West Nile viruses bearing 3'SL and envelope gene substitution mutations. Vaccine 2008, 26(November (47)):5981-5988.
22. Monath T.P., Liu J., Kanesa-Thasan N., Myers G.A., Nichols R., Deary A., et al. A live, attenuated recombinant West Nile virus vaccine. Proc Natl Acad Sci U S A 2006, 103(April (17)):6694-6699.
23. Pletnev A.G., Swayne D.E., Speicher J., Rumyantsev A.A., Murphy B.R. Chimeric West Nile/dengue virus vaccine candidate: preclinical evaluation in mice, geese and monkeys for safety and immunogenicity. Vaccine 2006, 24(September (40-41)):6392-6404.
24. Despres P., Combredet C., Frenkiel M.P., Lorin C., Brahic M., Tangy F. Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis. J Infect Dis 2005, 191(January (2)):207-214.
25. Martin J.E., Pierson T.C., Hubka S., Rucker S., Gordon I.J., Enama M.E., et al. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis 2007, 196(December (12)):1732-1740.
26. Lim C.K., Takasaki T., Kotaki A., Kurane I. Vero cell-derived inactivated West Nile (WN) vaccine induces protective immunity against lethal WN virus infection in mice and shows a facilitated neutralizing antibody response in mice previously immunized with Japanese encephalitis vaccine. Virology 2008, 374(April (1)):60-70.
27. Bonafe N., Rininger J.A., Chubet R.G., Foellmer H.G., Fader S., Anderson J.F., et al. A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+ cells. Vaccine 2009, 27(January (2)):213-222.
28. Lieberman M.M., Clements D.E., Ogata S., Wang G., Corpuz G., Wong T., et al. Preparation and immunogenic properties of a recombinant West Nile subunit vaccine. Vaccine 2007, 25(January (3)):414-423.
29. Martina B.E., Koraka P., van den Doel P., van Amerongen G., Rimmelzwaan G.F., Osterhaus A.D. Immunization with West Nile virus envelope domain III protects mice against lethal infection with homologous and heterologous virus. Vaccine 2008, 26(January (2)):153-157.
30. Gehrke R., Ecker M., Aberle S.W., Allison S.L., Heinz F.X., Mandl C.W. Incorporation of tick-borne encephalitis virus replicons into virus-like particles by a packaging cell line. J Virol 2003, 77(August (16)):8924-8933.
31. Konishi E., Fujii A., Mason P.W. Generation and characterization of a mammalian cell line continuously expressing Japanese encephalitis virus subviral particles. J Virol 2001, 75(March (5)):2204-2212.
32. Kojima A., Yasuda A., Asanuma H., Ishikawa T., Takamizawa A., Yasui K., et al. Stable high-producer cell clone expressing virus-like particles of the Japanese encephalitis virus e protein for a second-generation subunit vaccine. J Virol 2003, 77(August (16)):8745-8755.
33. Allison S.L., Tao Y.J., O'Riordain G., Mandl C.W., Harrison S.C., Heinz F.X. Two distinct size classes of immature and mature subviral particles from tick-borne encephalitis virus. J Virol 2003, 77(November (21)):11357-11366.
34. Patkar C.G., Jones C.T., Chang Y.H., Warrier R., Kuhn R.J. Functional requirements of the yellow fever virus capsid protein. J Virol 2007, 81(June (12)):6471-6481.
35. Ishikawa T., Konishi E. Mosquito cells infected with Japanese encephalitis virus release slowly-sedimenting hemagglutinin particles in association with intracellular formation of smooth membrane structures. Microbiol Immunol 2006, 50(3):211-223.
36. Junjhon J., Lausumpao M., Supasa S., Noisakran S., Songjaeng A., Saraithong P., et al. Differential modulation of prM cleavage, extracellular particle distribution, and virus infectivity by conserved residues at nonfurin consensus positions of the dengue virus pr-M junction. J Virol 2008, 82(November (21)):10776-10791.
37. Lobigs M., Lee E. Inefficient signalase cleavage promotes efficient nucleocapsid incorporation into budding flavivirus membranes. J Virol 2004, 78(January (1)):178-186.
38. Aberle J.H., Aberle S.W., Allison S.L., Stiasny K., Ecker M., Mandl C.W., et al. A DNA immunization model study with constructs expressing the tick-borne encephalitis virus envelope protein E in different physical forms. J Immunol 1999, 163(December (12)):6756-6761.
39. Aberle J.H., Aberle S.W., Kofler R.M., Mandl C.W. Humoral and cellular immune response to RNA immunization with flavivirus replicons derived from tick-borne encephalitis virus. J Virol 2005, 79(December (24)):15107-15113.
40. Heinz F.X., Allison S.L., Stiasny K., Schalich J., Holzmann H., Mandl C.W., et al. Recombinant and virion-derived soluble and particulate immunogens for vaccination against tick-borne encephalitis. Vaccine 1995, 13(December (17)):1636-1642.
41. Finkelman F.D., Holmes J., Katona I.M., Urban J.F., Beckmann M.P., Park L.S., et al. Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol 1990, 8:303-333.
42. Shrestha B., Diamond M.S. Role of CD8+ T cells in control of West Nile virus infection. J Virol 2004, 78(August (15)):8312-8321.